LY6H

Across TCGA pan-cancer cohorts, LY6H mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LY6H data layer compared with 26 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher LY6H mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LY6H expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, PDAC, and LSCC are the cancer types where LY6H mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.859	0.677	.013	4	view →
PDAC	DFS	Quartile	All	0.306	0.809	.047	2	view →
LSCC	DFS	Median	II,III,IV	0.543	0.899	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LY6H–GBM (DFS)

Open the GBM breakdown →